GIPAM tracks regularly published G-BA decisions on potential implications for future HTA/market access strategies. Ibrutinib, in combination with Venetoclax, was a recent assessment (July 2023) that has important strategic implication..

Feel free to contact us for more detailed insights!

We are excited to announce that our new European consultancy, GIPAM, became operational on the 1st of September, and along with it, we are more than happy to release our website.

Together with the ZKN institute at the University of Dresden and the German sickness fund AOK PLUS, a data set that links claims data since 2010 for more than 500 patients with all their relevant clinical MS data (medical record data) has been generated.